Background: Historically, histiocytic ulcerative (or granulomatous) colitis (HUC) of Boxer dogs was considered
Granulomatous colitis (GC) of Boxer dogs was first described by Van Kruiningen in a kennel of Boxer dogs in
1965.
1 Some subsequent reports of this disease use the term Histiocytic Ulcerative Colitis (HUC), [2] [3] [4] [5] and this term is more familiar to many veterinarians. The clinical hallmarks of the disease are severe large bowel diarrhea that is often accompanied by profound weight loss, anemia and hypoalbuminemia. 1-5 HUC, although rare, occurs world-wide with reported cases originating from Australia, Japan, North America and Europe. [1] [2] [3] [4] [5] [6] Boxer dogs are most commonly affected although other breeds such as Mastiff, Alaskan Malamute, Doberman
Pinscher, and French Bulldogs, are sporadically affected. [6] [7] [8] The pathognomonic lesion of HUC in Boxer dogs is mucosal infiltration with large numbers of macrophages staining positively with period-acid-Schiff (PAS), and is usually accompanied by mucosal ulceration and loss of goblet cells. 1 However, both the distribution and severity of lesions within the colon are variable, and in some cases they are focally distributed, and macrophages can be scarce and ulceration absent. 9, 10 Early reports describe a response of 6/9 dogs to chloramphenicol and the presence of intracellular bacteria within macrophages. 1, 11 However, these findings were poorly reproducible in subsequent studies 9, 10 and experimental attempts to reproduce HUC, by infecting Boxer dogs with Mycoplasma spp. isolated from colonic mucosa were unsuccessful. 12 In-depth pathological studies describe a loss of goblet cells and an increase in IgG 3 and IgG 4 plasma cells, CD 3 -T cells, and L 1 (macrophages and polymorphoneulcear granulocytes) and MHCII positive cells, similar to ulcerative colitis in people. 13 Thus HUC has until recently been regarded as an idiopathic immune-mediated disease that typically responds poorly to treatment with empirical therapies such as dietary change, antibiotics, and immunosuppressive agents. 4, 5 The poor response of HUC to immunosuppression led to a re-appraisal of antibiotic therapy, and there are now three independent studies that describe dramatic improvements in clinical signs and histological lesions of Boxer dogs treated with antibiotic protocols containing enrofloxacin. [14] [15] [16] These observations along with the discovery of a bacterial cause for the intestinal infiltration of PAS positive macrophages in people with
Whipple's disease 17 initiated the search for an infectious agent using contemporary culture-independent 4 sequencing, and histochemistry were used to guide subsequent FISH. Intramucosal Gram-negative coccobacilli were present in 100% of HUC samples from Boxer dogs but not controls, and invasive bacteria hybridized with FISH probes to E. coli. 16 Independent support for these findings is provided by the immunolocalization of E. coli to macrophages within the colons of 10/10 Boxer dogs with HUC. 18 E. coli strains isolated from affected Boxer dogs are novel in phylogeny, and have an adherent and invasive phenotype (AIEC) similar to strains isolated from people with Crohn's disease. 16, 19, 20 These findings suggest that E. coli invasion may play a critical role in the initiation and/or progression of HUC in Boxer dogs, likely facilitated by a breed-specific susceptibility.
It is against this background that we sought to determine the temporal association of clinical and histological response to the presence or absence of intramucosal E. coli in Boxer dogs with HUC before and after treatment with enrofloxacin.
Materials and Methods
Seven Boxers with signs of colitis referred to MUVTH (dogs [1] [2] [3] [4] [5] E. coli using methods described previously. 20 Antimicrobial sensitivity of E. coli was determined by disk diffusion. (Figures 1 and 3) . Intramucosal E. coli was detected in colonic 8 mucosal biospies from the dog (dog 7) that had become clinically unresponsive to treatment with enrofloxacin. Re-evaluation of colonic biopsies following treatment with amoxicillin-clavulanate f , showed persistence of intramucosal bacteria, though they did appear reduced in number.
Discussion
The clinical response of Boxer dogs with HUC to antibiotic regimens containing enrofloxacin a strongly suggests bacterial involvement in the inflammatory process. [14] [15] [16] This possibility is significantly strengthened by the recent discovery of invasive E. coli within the colonic mucosa and macrophages of affected Boxer dogs, but not dogs with other forms of colitis. 16 Our observations that colonic biopsies obtained during the initial diagnostic evaluation of 7 HUC affected Boxers contained intramucosal E. coli provides independent confirmation of these previous findings. The inclusion of dogs from Australia and the USA in the present study, and dogs from the UK and USA in the previous study 16 27 It is noteworthy that the E. coli strains isolated from Boxer dogs are strikingly similar to those implicated in Crohn's ileitis, [16] [17] [18] [19] [20] 24 in that they are able to invade, persist and replicate in epithelial cells and macrophages and evoke the production of pro-inflammatory cytokines such as TNF-α, IFN-γ and IL8. 19, 20, 28 These characteristics are generally associated with pathogenic bacteria, and it seems likely that this emergent group of adherent and invasive E. coli (AIEC) are opportunistic pathogens able to exploit a susceptible individual rather than harmless commensals. 20, 25, 28 This possibility is consistent with the prevailing view that inflammatory bowel disease is the result of an over-exuberant inflammatory response to a subset of resident enteric bacteria in a genetically susceptible individual. 29, 30 Genetic polymorphisms associated with granulomatous intestinal inflammation in people involve defective intracellular processing of bacterial components such as polymorphisms in the intracytosolic muramyl dipeptide receptor NOD2, and autophagy genes such as ATG16L1, and an overactive mucosal inflammatory response (e.g. IL-23r promoting loss of oral tolerance). 31 Since HUC in dogs is remarkably breed-specific it may be due to a heritable anomaly in Boxer dogs that confers susceptibility to invasion and persistence of AIEC within the colonic mucosa. As
Boxer dogs are also prone to other granulomatous diseases such as intestinal and systemic protothecosis and cutaneous intracellular mycobacteria (canine leproid granuloma syndrome), 32, 33 it is possible that Boxers have a genetic defect in how they respond to granuloma-inducing microorganisms in general, e.g. defective bacterial
killing. Further study is needed to identify the host and bacterial factors related to invasion and persistence of E. coli in HUC susceptible Boxers.
Our finding that clinical remission in response to enrofloxacin a correlates with the eradication of invasive E.coli and precedes complete histologic resolution of inflammation highlights the importance of eliminating E. coli infection in Boxers with HUC. Serial evaluation of dog 1, where the ongoing inflammation observed at 2 weeks had almost completely resolved at 7 months suggests the lag between bacterial eradication and normalization of colonic histology reflects the time taken to heal and remodel the severely damaged mucosa. These observations are similar to findings in people with Whipple's disease where regression of PAS positivity lags behind eradication of Trophyrema whipplei. 34 In the present study, resistance to enrofloxacin a was demonstrated in two E. coli strains isolated from the colonic mucosa of a dog whose clinical signs recurred after an initial response to enrofloxacin. The development of resistance to enrofloxacin a has been extensively demonstrated in dogs with E. coli and other
Enterobacteriaceae infections [35] [36] [37] [38] and often involves acquisition of resistance plasmids. 38 Interestingly, the dog that relapsed had received several short courses of treatment with enrofloxacin (2-4 weeks) and it is possible that repeated withdrawal of enrofloxacin a prior to complete eradication of infection facilitated recrudescence and subsequently development of enrofloxacin a resistance. Short-term treatment of this dog with amoxicillin-clavulanate g , based on the results of antimicrobial susceptibility testing, resulted in a reduction in intramucosal E. coli and partial histologic improvement, but this did not translate to clinical improvement.
While it is possible that a longer duration of treatment may have been effective it is important to consider that differences in the ability of antibiotics to penetrate infected macrophages may also affect outcome. Evaluation of the ability of antibiotics (at peak serum concentrations) to kill E. coli isolated from colonic Crohn's disease within J774-A1 macrophages indicates greatest efficacy of ciprofloxacin, with decreasing impact of rifampicin, tetracycline, trimethoprim, clarithromycin and azithromycin. 39 This study also found the combination of ciprofloxacin, tetracycline and trimethoprim was more effective than ciprofloxacin alone, and that ampicillin was not effective against intra-cellular CD associated E. coli. Hence, the ability to effectively penetrate and kill E. (a, c, e) revealed multifocal intramucosal bacteria that hybridized with a Cy-3 labeled probe to E. coli (bacteria are orange, DAPI stained nuclei are blue). Many of the E. coli appeared to be within
